Paola Gazzola

Genoa, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

Comparative Effectiveness of Cladribine and S1P Receptor Modulators in Treatment-Naive Relapsing-Remitting MS.

Comparative Effectiveness of Cladribine and S1P Receptor Modulators in Treatment-Naive Relapsing-Remitting MS.

Journal: JAMA network open
Published: November 03, 2025

Impact of anodal tDCS and virtual reality on cognitive dysfunction in patients with Multiple Sclerosis: Protocol of a double blind, randomized, prospective, controlled study.

Impact of anodal tDCS and virtual reality on cognitive dysfunction in patients with Multiple Sclerosis: Protocol of a double blind, randomized, prospective, controlled study.

Journal: PloS one
Published: October 30, 2025

Effectiveness of Rituximab in rElapsiNg Multiple SclErosis previously treated with hiGhly-Active Disease modifying thErapies (RENEGADE study).

Effectiveness of Rituximab in rElapsiNg Multiple SclErosis previously treated with hiGhly-Active Disease modifying thErapies (RENEGADE study).

Journal: Journal of neurology
Published: July 16, 2025

Late-onset multiple sclerosis: disability trajectories in relapsing-remitting patients of the Italian MS Registry.

Late-onset multiple sclerosis: disability trajectories in relapsing-remitting patients of the Italian MS Registry.

Journal: Journal of neurology
Published: September 25, 2023

Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry.

Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry.

Journal: Journal of neurology
Published: August 08, 2023

Antibody response elicited by the SARS-CoV-2 vaccine booster in patients with multiple sclerosis: Who gains from it?

Antibody response elicited by the SARS-CoV-2 vaccine booster in patients with multiple sclerosis: Who gains from it?

Journal: European journal of neurology
Published: February 10, 2023

Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis.

Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis.

Journal: JAMA neurology
Published: July 25, 2022

Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy.

Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy.

Journal: EBioMedicine
Published: February 23, 2022

Do patients' and referral centers' characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register.

Do patients' and referral centers' characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register.

Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Published: February 17, 2022

Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies.

Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies.

Journal: EBioMedicine
Published: July 15, 2021

mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis.

mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis.

Journal: Journal of neurology, neurosurgery, and psychiatry
Published: May 21, 2021

Tailoring B cell depletion therapy in MS according to memory B cell monitoring.

Tailoring B cell depletion therapy in MS according to memory B cell monitoring.

Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: January 20, 2020
Showing 1-12 of 14

Last Updated: 09/26/2026